Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Go back to Vanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.95 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.95 | 52 Week High | $18.00 | |||
| Open | $5.95 | 52 Week Low | $6.91 | |||
| Day High | $5.95 | P/E | N/A | |||
| Day Low | $5.95 | EPS | $-0.67 | |||
| Volume | 289 | |||||
